Transvaginal mesh cases continue to affect women in St. Louis, Missouri, and across the country because pelvic injuries rarely follow a clean legal timeline. Over 100,000 lawsuits have been filed against manufacturers of mesh implants used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI), with an estimated $8 billion paid in settlements and verdicts to date. While about 95% of cases have been resolved and the major federal MDLs have closed, new claims continue to be filed in state courts nationwide. In February 2023, the U.S. Supreme Court left standing a $302 million California judgment against Johnson & Johnson for deceptive marketing of its pelvic mesh products. The FDA warned in 2011 that serious complications from transvaginal mesh were “not rare,” and in April 2019, the agency ordered all remaining transvaginal prolapse mesh products off the U.S. market.
Some patients develop erosion, chronic pain, bleeding, urinary problems, or painful intercourse years after surgery. Others learn the implant is involved only after specialist care or revision surgery. Families and women exploring a transvaginal mesh lawsuit can review operative notes, diagnosis dates, revision findings, and filing deadlines to determine whether they may still have a claim. State courts still review these cases through local rules on deadlines, warnings, causation, and proof, and each file depends on medical history, product records, and documented harm.
State Filing Rules Matter
Each state controls its own filing deadlines for injury claims. Some periods begin at implantation, while others may start when harm should have been discovered. That difference carries weight in mesh cases. Pelvic pain, infections, bleeding, or bladder symptoms can be blamed on aging, childbirth trauma, menopause, or unrelated disease before an implant is reviewed.
Medical Injuries Can Surface Late
Mesh-related harm can appear slowly. Tissue exposure may be found during an exam years after placement. Nerve pain, scarring, painful intercourse, and recurring infections may develop in stages. Because symptoms overlap with common pelvic conditions, courts often examine when a reasonable patient, clinician, or specialist could have linked the problem to the device.
Device Records Still Drive Proof
Product identification remains a core issue. Operative notes, implant stickers, hospital charts, and revision reports can show the manufacturer, model, lot number, and intended use. Those details connect a patient’s injury to a particular device. Without that chain, causation becomes harder to prove. With it, warnings and design history can be compared against the medical outcome.
State Judges Apply Local Standards
Product liability rules vary by state. One court may focus on whether warnings gave surgeons enough risk information. Another may ask if a safer design was practical at the time of sale. Expert testimony also faces different screening standards. These legal differences explain why similar mesh claims may move at different speeds across courts.
Settlements Did Not Cover Everyone
Large settlement programs resolved many earlier claims, but coverage was never universal. Some patients received diagnoses after settlement windows closed. Others lacked records, needed further care, or had implants outside certain product groups. The FDA encourages patients and healthcare professionals to report device problems through MedWatch, its safety information and adverse event reporting program, and those reports can help support both individual claims and broader safety review. A later-filed case may still require court review when medical proof, device identity, and state deadlines support further evaluation.
FDA Action Shapes the Record
In April 2019, federal regulators ordered remaining pelvic organ prolapse mesh products off the United States market. That step did not decide private lawsuits. It did, however, create an important regulatory marker. Current cases may review earlier safety reports, surgeon training, patient warnings, postmarket studies, and how risk information was shared before removal.
Why New Cases Still Appear
New filings usually reflect late discovery rather than renewed mass litigation. A patient may receive a clear explanation only after imaging, pelvic examination, or revision surgery. Medical records may then connect long-standing symptoms to mesh exposure, contraction, or tissue injury. State courts handle these fact-heavy claims because timing and causation differ from person to person.
Evidence Often Starts With Care
Medical treatment usually comes before legal review. Clinicians may document exposure, scarring, pelvic floor tenderness, nerve symptoms, infection patterns, urinary changes, or surgical findings. That record helps separate implant-related harm from other gynecologic or urologic conditions. Expert witnesses then explain how the device may have caused injury and why competing causes appear less likely.
What Active Litigation Means
Active state litigation does not mean every claim has merit. It means courts still receive cases that require individual review. Judges may dismiss weak filings, approve negotiated resolutions, or allow disputed claims to proceed toward trial. Ongoing activity shows that mesh injuries remain medically and legally significant, even after the major federal phase ended.
Conclusion
These lawsuits remain active because unresolved pelvic injuries do not fit one federal schedule. State courts continue to assess filing rules, device records, expert opinions, and patient-specific medical histories. The remaining claims are usually narrow, documented, and evidence-driven. For the health system, they reinforce a practical lesson: implant tracking, plain risk warnings, and long-term follow-up matter after surgical repair. That concern reaches patients, clinicians, courts, and manufacturers alike.
